STAT1 Gain of Function, Type 1 Diabetes, and Reversal with JAK Inhibition

N Engl J Med. 2020 Oct 8;383(15):1494-1496. doi: 10.1056/NEJMc2022226.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / genetics
  • Gain of Function Mutation*
  • Humans
  • Janus Kinase Inhibitors / therapeutic use*
  • Male
  • Nitriles
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • STAT1 Transcription Factor / genetics*

Substances

  • Janus Kinase Inhibitors
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • ruxolitinib